Publication date: 26/04/2018
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the first quarter of 2018 and an outlook for the remainder of the year.
Commenting on the Q1 business update, Herman Verrelst, Chief Executive Officer of Biocartis, said:
"Our performance in the first quarter paves the way for the realization of our 2018 targets. In particular, we saw great interest amongst top tier oncology hospitals in the US. Support from these hospitals and their key opinion leaders will be an important driver in realizing a broad market adoption of our system. We also established a US R&D center in New Jersey, which shows our dedication in the US market and will help realize efficiencies in the execution of existing and expected menu partnerships, another key driver for further market adoption. As we strengthen and grow the organization at all levels, we are also proposing a new board composition at our upcoming shareholders' meeting to include five new independent board members, each bringing new and complementary experience and expertise to our board. On behalf of the entire organization, I would like to thank all the outgoing board members for their valued contribution in the past years. I look forward to working with the new board in further laying the foundations for long-term growth."
Menu and partnership update
More information on the profiles of the proposed new board members can be found on the Biocartis website. The proposed board composition will allow for a transition towards a board of directors consisting predominantly of independent directors.
Financial calendar 2018
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) system is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) system in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers fourteen oncology assays and two infectious disease assays in Europe. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.